Product Description
AS-03 is being developed by GlaxoSmithKline for the prevention of influenza. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01578317?term=AS-03&draw=2&rank=2)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Colombia, France, Germany, Honduras, Korea, Nepal, New Zealand, Philippines, Spain, Thailand, Ukraine, United Kingdom, United States, Vietnam
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: COVID-19
Phase 2: Hepatitis A|Hepatitis B|Kidney Transplant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT05561673 | P2 |
Completed |
Hepatitis B|Hepatitis A |
2024-11-29 |
|
| CPAT-SG | P2 |
Active, not recruiting |
COVID-19|Kidney Transplant |
2024-02-28 |
|
| GBP510_003 | P3 |
Completed |
COVID-19 |
2023-10-02 |
39% |
| GBP510_003 | P3 |
Completed |
COVID-19 |
2023-10-02 |
39% |
| GBP510_004 | P3 |
Completed |
COVID-19 |
2023-08-22 |